Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future

Glioblastoma (GBM) is a highly aggressive primary brain tumor that is largely refractory to treatment and, therefore, invariably relapses. GBM patients have a median overall survival of 15 months and, given this devastating prognosis, there is a high need for therapy improvement. One of the therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kringel, Rebecca, Lamszus, Katrin, Mohme, Malte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340625/
https://www.ncbi.nlm.nih.gov/pubmed/37443804
http://dx.doi.org/10.3390/cells12131770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340625/
https://www.ncbi.nlm.nih.gov/pubmed/37443804
http://dx.doi.org/10.3390/cells12131770

Ejemplares similares